Apyx Medical (APYX) Current Deferred Revenue (2019 - 2025)

Apyx Medical (APYX) has reported Current Deferred Revenue for 7 consecutive years, with $1.7 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue fell 15.0% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (down 15.0% YoY), and the FY2025 full-year result was $1.7 million, down 15.0% from the prior year.
• Current Deferred Revenue retreated to $1.7 million in Q4 2025 per APYX's latest filing, from $2.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $2.3 million in Q4 2022 and bottomed at $1.7 million in Q4 2023.
• Historically, Current Deferred Revenue has averaged $1.9 million across 5 years, with a median of $1.9 million in 2021.
• The sharpest annual moves came in 2021 and 2023: Current Deferred Revenue jumped 216.67% in 2021, then fell 26.09% in 2023.
• Over 5 years, Current Deferred Revenue stood at $1.9 million in 2021, then rose by 21.05% to $2.3 million in 2022, then fell by 26.09% to $1.7 million in 2023, then gained by 17.65% to $2.0 million in 2024, then decreased by 15.0% to $1.7 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $1.7 million, $2.0 million, and $1.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.